We describe the development of OncoFAP, an ultra-high-affinity ligand of fibroblast activation
protein (FAP) for targeting applications with pan-tumoral potential. OncoFAP binds to …

The availability of ultra-high-affinity small organic ligands, which are specific to accessible
cancer antigens, is crucially important to enable efficient and selective tumor targeting …

Background In this study, we describe the generation of a fully human monoclonal antibody (named
‘7NP2’) targeting human fibroblast activation protein (FAP), an antigen expressed in …

Purpose: Small molecule drug conjugates (SMDC) are modular anticancer prodrugs that
include a tumor-targeting small organic ligand, a cleavable linker, and a potent cytotoxic agent. …

… Corbellari, Riccardo a,,b,,* ; Nadal, Lisa a,,b,,* ; Villa, Alessandra b ; Neri, Dario c ; De Luca,
Roberto … * Riccardo Corbellari and Lisa Nadal contributed equally to the writing of this article. …

Antibody-based delivery of bioactive molecules represents a promising strategy for the
improvement of cancer immunotherapy. Here, we describe the generation and characterization of …

Interferon-gamma (IFNγ) is one of the central cytokines produced by the innate and
adaptive immune systems. IFNγ directly favors tumor growth control by enhancing the …

Programmed cell death protein 1 (PD‐1) is an immunoregulatory target which is recognized
by different monoclonal antibodies, approved for the therapy of multiple types of cancer. …

Background Fibroblast Activation Protein (FAP) has been described as the “next billion-dollar
nuclear theranostics target” 1 , since more than 28 different tumor types have successfully …

Cancer immunotherapy has revolutionized the field of oncology by giving the possibility to
ligands (eg, antibodies) to selectively target tumor antigens and accumulate at the site of the …